Hepatitis B virus seroprevalence among HIV-infected patients receiving combination antiretroviral therapy three decades after universal neonatal hepatitis B immunization

doi:10.1016/j.jmii.2019.10.005BY-

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/23421

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23421

Title:	Hepatitis B virus seroprevalence among HIV-infected patients receiving combination antiretroviral therapy three decades after universal neonatal hepatitis B immunization
Authors:	Lin, JJ;Lin, KY;Tang, HJ;Lin, SP;Lee, YC;Liu, CE;Huang, YS;Wang, NC;Li, CW;Ko, WC;Yang, HJ;Lee, YT;Hung, CC
Keywords:	Men who have sex with men;Neonatal vaccination;Sexually transmitted infection;Vertical transmission;Viral hepatitis
Date:	2021
Issue Date:	2022-08-05T09:37:00Z (UTC)
Publisher:	ELSEVIER TAIWAN
ISSN:	1684-1182
Abstract:	Background/purpose: This multicenter study aimed to evaluate the seroprevalence of hepatitis B virus (HBV) and the use of combination antiretroviral therapy (cART) among patients receiving HIV care in Taiwan. Methods: We retrospectively reviewed the medical records of HIV-infected adult patients who initiated cART at 11 designated hospitals in Taiwan between 2012 and 2016. The clinical information collected included serological profiles on HBV, hepatitis C virus (HCV), and syphilis, plasma HIV RNA load, nadir CD4 cell count, and antiretrovirals with activity against both HBV and HIV (tenofovir disoproxil fumarate [TDF], lamivudine [LAM], and emtricitabine [FTC]). Results: We analyzed 1800 HIV-infected patients; 1742 (96.8%) were male and 794 (44.1%) were born after July, 1986, when nationwide universal neonatal HBV vaccination was implemented. HBsAg positive results were 11.6% (209/1800), which decreased significantly from 18.1% (182/1006) in those born before July 1986 to 3.4% (27/794) in those born after. In multi variable analysis, HBsAg positivity was significantly associated with age (adjusted odds ratio [aOR] 1.06, 95% confidence interval [CI] 1.05-1.08), CD4S200 cells/mL (aOR 0.73, 95% CI 0.53-0.99), and HCV seropositivity (aOR 1.62, 95% CI 1.06-2.50 ). Of 209 HBV/HIVcoinfected patients, 31.1% started cART containing only LAM with anti-HBV activity, while 68.9% started cART containing TDF plus LAM or coformulated TDF/FTC. Conclusions: The overall prevalence of HBV/HIV coinfection remained high among HIV infected patients in Taiwan. Despite recommendations of the HIV treatment guidelines for the management of HBV infection, a substantial proportion of HIV/HBV-coinfected patients received cART containing only LAM for HBV infection. Copyright & ordf; 2019, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
URI:	http://dx.doi.org/10.1016/j.jmii.2019.10.005BY- https://www.webofscience.com/wos/woscc/full-record/WOS:000643001600010 https://ir.csmu.edu.tw:8080/handle/310902500/23421
Relation:	JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION ,2021,v54,issue 2, P228-237
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	151	View/Open

Loading...